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OBJECTIVE—To compare fasting plasma glucose (FPG) and HbA1c in identifying and pre-
dicting type 2 diabetes in a population with high rates of diabetes.
RESEARCH DESIGN AND METHODS—Diabetes was deﬁned as an FPG level $126
mg/dL or an HbA1c level $6.5%. Data collected from the baseline and second exams (1989–
1995) of the Strong Heart Study were used.
RESULTS—For cases of diabetes identiﬁed by FPG $126 mg/dL, using HbA1c $6.5% at the
initialand4-yearfollow-updiabetesscreenings(orinidentifyingincidentcasesin4years)among
undiagnosed participants left 46% and 59% of cases of diabetes undetected, respectively,
whereas for cases identiﬁed by HbA1c $6.5%, using FPG $126 mg/dL left 11% and 59% un-
identiﬁed, respectively. Age, waist circumference, urinary albumin-to-creatinine ratio, and base-
line FPG and HbA1c levels were common signiﬁcant risk factors for incident diabetes deﬁned by
eitherFPGorHbA1c;triglyceride levelsweresigniﬁcantfordiabetesdeﬁnedbyHbA1calone,and
blood pressureand siblinghistoryof diabetes were signiﬁcant for diabetes deﬁnedbyFPGalone.
UsingboththebaselineFPGandHbA1cindiabetespredictionidentiﬁedmorepeopleatriskthan
using either measure alone.
CONCLUSIONS—Among undiagnosed participants, using HbA1c alone in initial diabetes
screeningidentiﬁesfewercasesofdiabetesthanFPG,andusingeitherFPGorHbA1calonecannot
effectively identifydiabetesina4-year periodicsuccessive diabetesscreening or incident casesof
diabetes in 4 years. Using both criteria may identify more people at risk. The proposed models
using the commonly available clinical measures can be applied to assessing the risk of incident
diabetes using either criterion.
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T
ype 2 diabetes has emerged as an
important public health and eco-
nomic problem in the U.S. More
than 18 million Americans have diabetes
and are at risk for related complications
including heart disease, stroke, retinopa-
thy, leg vessel disease, and kidney disease
(1). Currently available therapeutic
strategies in diabetes are only partially
successful in preventing its complica-
tions. Therefore, diabetes screening in
undiagnosed participants and early iden-
tiﬁcationofthoseathighriskforinterven-
tion to prevent diabetes onset is very
important for reducing diabetes-associated
complications and medical care costs.
Criteria proposed for diagnosing in-
cident diabetes by the American Diabetes
Association (ADA) (2) based on fasting
plasma glucose (FPG) have been used
for a long time. Recently, an International
Expert Committee (3) recommended a
criterion based on HbA1c.T h ec u t o f f
point of an HbA1c $6.5% suggested in
their report was based on the association
of HbA1c with the prevalence of retinop-
athy from large cross-sectional studies
(3). The ADA recently added HbA1c as a
diagnostic criterion of diabetes and sug-
gested using either criterion (4). There-
fore, it is important to know how these
criteria perform in identifying prevalent
diabetes in initial and successive diabetes
screenings among undiagnosed partici-
pants and incident diabetic case subjects
in a period of time and which risk factors
predict incident diabetes deﬁned by these
criteria.
This report used longitudinal data
from two exams (1989–1992 and 1993–
1995) of the Strong Heart Study (SHS), a
study to assess the prevalence and inci-
dence of cardiovascular disease (CVD)
and its risk factors in American Indians
(5). This population has high rates of di-
abetes,anddatafromthispopulationmay
be considered to be reﬂective of other
populations who are at high risk for
diabetes and diabetic CVD (6,7). This re-
search compares the diagnosis of diabetes
by HbA1c or/and FPG and the risk factors
for incident diabetes deﬁned by the three
criteria and develops prediction equa-
tions for incident diabetes using baseline
HbA1c,F P G ,o rb o t h .
RESEARCH DESIGN AND
METHODS—A total of 4,549 Ameri-
can Indian men and women, aged 45–74
years, in 13 Indian tribes/communities in
Arizona, North/South Dakota, and Okla-
homa, participated in the SHS baseline
examinationfrom1989to1992afterpro-
viding written informed consent. The
study was approved by all participating
Indian tribes/communities and the Insti-
tutional Review Boards of the participat-
ing institutions and the Indian Health
Service. The cohort was followed and
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ORIGINAL ARTICLEreexamined in 1993–1995. The design
and methods of the SHS have been pre-
viouslyreportedindetail(5).Brieﬂy,each
examination included a personal inter-
view and a physical examination. Blood
was drawn at each examination after a
12-h fast, and total cholesterol (TC),
LDL cholesterol (LDL-C), HDL cholesterol
(HDL-C), triglycerides (TGs), and FPG
were measured. Diabetes status was de-
ﬁned by ADA 2004 criteria based on
FPG (denoted as FPG-DM) (2) as diabetes
ifFPG$126mg/dLorifondiabetesmed-
ications, as impaired fasting glucose (IFG)
(or prediabetes) if 100 # FPG , 126 mg/
dL, and as normal fasting plasma glucose
(NFG) if FPG ,100 mg/dL; by Interna-
tional Expert Committee criteria based
on HbA1c (denoted as A1C-DM) (3) as di-
abetes if HbA1c $6.5% or if on diabetes
medications, prediabetes if 6.0 # HbA1c
, 6.5%, and nondiabetes otherwise; and
by current ADA criteria based on both
HbA1c and FPG (denoted as FPG/A1C-
DM) (4) as diabetes if HbA1c $6.5% or
FPG $126 mg/dL or if on diabetes medi-
cations and nondiabetes otherwise. A
urine sample was taken to measure albu-
minandcreatinine.Albuminuriawasclas-
siﬁed by urinary albumin-to-creatinine
ratio (UACR) as microalbuminuria if 30
# UACR , 300 mg/g and macroalbumi-
nuria if UACR $300 mg/g. Obesity status
was deﬁned as obese if BMI $30 kg/m
2,
overweight if 25 # BMI , 30 kg/m
2, and
normal if BMI ,25 kg/m
2.T h r e em e a -
surements of systolic blood pressure
(SBP) and diastolic blood pressure (DBP)
were taken on the right arm with an ap-
propriately sized cuff using a Baum mer-
cury sphygmomanometer (W.A. Baum
Co., Copiague, NY) after the participant
rested in a seated position for 5 min. The
average of the second and third measure-
ments was used as the blood pressure
value for each participant. According to
SeventhReportoftheJointNationalCom-
mitteeonPrevention,Detection,Evaluation,
and Treatment of High Blood Pressure
(JNC-7) criteria (8), hypertension (HTN)
was deﬁned as SBP/DBP $140/90 mmHg
or on antihypertensive medications, nor-
mal if SBP ,120 mmHg and DBP ,80
mmHg, and prehypertension (Pre-HTN)
otherwise. Leisure-time activities were
measured at the baseline exam by the av-
erage exercise hours in the past week
(AEHPW).
Metabolic syndrome traits described
by the National Cholesterol Education
Program Adult Treatment Panel III (ATP
III) criteria (9) were also used in
classiﬁcation. Participants with SBP/DBP
$130/85 mmHg or on treatment for
hypertension were considered as having
elevated blood pressure; waist circum-
ference (WAIST) .102 cm in men or
.88 cm in women was considered high
(highWAIST); fasting TG $150 mg/dL
was considered hypertriglyceridemia
(hyperTG); and HDL-C ,40 mg/dL in
men or ,50 mg/dL in women was con-
sidered low (lowHDL-C).
Data collected at the baseline and
second exams from those participants
who had HbA1c and FPG measured and
did not receive insulin treatment or an
oral agent for diabetes, were not on renal
dialysis, and did not have a kidney trans-
plant were used to compare the perfor-
mances of HbA1c and FPG in identifying
diabetes in undiagnosed participants.
The risk factors data from the baseline
exam and the incident diabetes status
data from the second exam collected
from participants without FPG-DM,
A1C-DM, or FPG/A1C-DM at the baseline
examwereusedtoexplore signiﬁcantpre-
dictors for cumulative incident FPG-DM,
A1C-DM, and FPG/A1C-DM, respec-
tively, and to compare effects of the base-




performances of HbA1c and FPG in iden-
tifying diabetes in undiagnosed partici-
pants. Logistic regression models (10)
were used to compare risks of cumulative
incident diabetes among subgroups of
each risk factor after adjusting for age,
sex, and center and to identify risk factors
and build predictive models for cumula-
tive incident FPG-DM, A1C-DM, and
FPG/A1C-DM. Model-developing proce-
dures were as follows: Step 1, candidate
variables/risk factors for incident diabetes
wereselectedamongallpotentialcategor-
ical and continuous variables in the SHS
data by a stepwise selection method with
P = 0.05 for both entry and retention.
These variables/risk factors included
those reported in the literature (11–13)
(i.e., age, sex, height, BMI, WAIST, SBP,
DBP, current smoking status, hyperten-
sion status, parental or sibling history of
diabetes, FPG, TC, LDL-C, HDL-C, TG,
and the categorical metabolic syndrome
traits) and additional variables (AEHPW,
yearsofeducation,currentalcoholintake,
HbA1c,a n dU A C R ) .S t e p2 ,t h eﬁnal
model was derived by adding those addi-
tional signiﬁcant ones that were selected
by the stepwise method again among the
squares and interactions of those selected
candidate continuous variables in the
model selected at Step 1. Step 1 was for
selecting an optimal subset of signiﬁcant
and independent risk factors of incident
diabetesamongallpotentialsubsetsofthe
candidate risk factors. Step 2 considered
potential interaction and nonlinear rela-
tions of the selected candidate variables
with incident diabetes. The ability of the
predictive models to discriminate partic-
ipants who will or will not develop diabe-
tes was assessed by the area under the
receiver operating characteristic curve
(AROC) (14). An AROC value $0.70 in-
dicates good discrimination ability. The
performance of the proposed models
was also assessed for calibration by com-
paring the number of observed and pre-
dicted diabetes events in 4 years using a
Hosmer-Lemeshow statistic (15). A value
of this statistic ,20 is considered good
calibration. The discrimination and cali-
bration abilities of the derived predictive
models were further internally validated
by using internal bootstrap resampling
(1,000 samples with the same size as the
original cohort and with replacement)
method described by Harrell et al. (16).
Thebootstrap-correctedAROCandPvalue
of the Hosmer-Lemeshow statistic were
used in assessing internal validation (16).
Tocompareperformances oftwodifferent
predictive models, we compared their
AROCs (17). Statistical signiﬁcance was
deﬁnedastwo-tailedP,0.05foralltests
unless otherwise speciﬁed. SAS 9.1 was
used for all analyses.
RESULTS—Thebaselinecharacteristics
from the SHS have been reported pre-
viously (6). Table 1 shows HbA1c by FPG
classiﬁcation based on data from the SHS
participants who had HbA1c and FPG
measured and did not receive diabetes
medications, were not on renal dialysis,
and did not have a kidney transplant at
the baseline exam (n =2 , 8 4 9 )o ra tt h e
second exam (n =1 , 6 7 0a f t e re x c l u d i n g
also all participants who had FPG/A1C-
DM at the baseline exam). Therefore, the
data from the baseline exam represent re-
sults of initial diabetes screening by using
HbA1c or FPG in undiagnosed partici-
pants, whereas the data from the second
exam,anaverageof4yearsaftertheinitial
screening,representincidentcasesinpar-
ticipants without diabetes at baseline.
For prevalent cases of diabetes, based
on the results from the baseline exam,
HbA1c ($6.5%) identiﬁed only 54%
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FPG/HbA1c in identifying and predicting diabetes[314/(314+73+167+25)]ofthoseiden-
tiﬁed by FPG ($126 mg/dL), whereas
FPG identiﬁed 89% [314/(314 + 33 + 4)]
of those diagnosed by HbA1c (Table 1).
Using HbA1c alone identiﬁed only 57%
[(314 + 33 + 4)/(314 + 73 + 167 + 25 +
33 + 4)] of all prevalent FPG/A1C-DM
cases, whereas using FPG alone identiﬁed
94% [(314 + 73 + 167 + 25)/616]. For
identifying cases of incident diabetes in
4 years, based on the results from the sec-
ond exam, either HbA1c or FPG identiﬁed
only 41% of those diagnosed by the other.
Using either HbA1c or FPG alone iden-
tiﬁed 63% (175/279) of all incident
FPG/A1C-DM cases. Because the data
fromthesecondexamalsorepresentresults
from a 4-year periodic successive diabetes
screening in participants without diabetes
atbaseline,thisisalsoimpliedthatforiden-
tifying cases of prevalent diabetes in a
4-year periodic successive diabetes screen-
ing in undiagnosed participants, using ei-
ther FPG or HbA1c alone identiﬁed only
63% of all FPG/A1C-DM cases.
For cases of prevalent prediabetes in
the baseline exam, among undiagnosed
participants HbA1c (6–6.4%) identiﬁed
7% of those diagnosed by FPG (100–
125 mg/dL), whereas FPG (100–125
mg/dL)identiﬁed47%ofthosediagnosed
by HbA1c (6–6.4%); in the second exam,
HbA1c identiﬁed 8% of those diagnosed
by FPG,and FPG diagnosed 54% of those
diagnosed by HbA1c.
To examine how A1C-DM criterion
f r o mas i n g l ee x a mr e l a t et ot h ec l i n i c a l
requirement of a repeat value for diagno-
sis, we have evaluated those 277 undiag-
nosed baseline diabetic participants who
had HbA1c $6.5% at the baseline exam
and who also participated in the second
exam. A total of 246 (88.8%) of the 277
undiagnosed participants received diabe-
tes treatments (182) before the second
examorstillhadHbA1c$6.5%atthesec-
ond exam; 258 (93.1%) of the 277 re-
ceived diabetes treatments or had either
HbA1c $6.5%orFPG$126mg/dLatthe
second exam.
Table 2 compares the risks of devel-
oping incident A1C-DM, or FPG-DM, or
FPG/A1C-DM in 4 years among sub-
groups of each risk factor commonly
available in clinical practice after adjust-
ing for age, sex, and center. For example,
participants with 6.0% # HbA1c , 6.5%
at the baseline exam had 5.89 times
higher risk of developing A1C-DM in
4yearsthanthosewithHbA 1c,6.0%;par-
ticipants with IFG at the baseline exam
had 3.12 times higher risk of developing
FPG-DM in 4 years than those with NFG.
The table also shows odds ratios among
strata of each risk factor for incident FPG/
A1C-DM. From these adjusted univariate
analyses, in addition to baseline glycemia,
hypertension, obesity, highWAIST, fam-
ily history, micro/macro-albuminuria,
hyperTG, and lowHDL-C were all signif-
icant risk factors for incident diabetes
identiﬁed by either criterion.
Predictive models for cumulative in-
cidenceofdiabetesin4yearsareshownin
Table3.Age,waistcircumference,UACR,
and baseline FPG and HbA1c levels were
common signiﬁcant risk factors for inci-
dent diabetes deﬁned by either FPG or
HbA1c; TG was an independent predictor
for incident A1C-DM alone, and elevated
blood pressure and sibling history of
diabetes were independent predictors of
incident FPG-DM alone. In these multi-
variate models, age was signiﬁcantly and
negatively associated with incident A1C-
DM, FPG-DM, or FPG/A1C-DM. HbA1c
was positively associated with incident
FPG-DM. HbA1c was also associated neg-
atively when ,4.66% and positively
when .4.66% with incident A1C-DM,
as the quadratic function of HbA1c in
the model decreased when HbA1c was
,4.66% and increased when .4.66%.
Similarly, for incident FPG/A1C-DM,
the inﬂection point of HbA1c was
4.73%. UACR was associated negatively
when UACR was ,1a n dp o s i t i v e l y
when UACR was .1 with incident diabe-
tesbyallthreecriteria,asthefunctionLog
(UACR) 3 Log(UACR) was decreased
when UACR was ,1 and increased
when UACR was .1.
The AROC was 0.75 (P , 0.0001)
from the predictive model of incident
A1C-DM, indicating good discrimination
ability. The Hosmer-Lemeshow statistic
of the model was 11.23 (P = 0.1889), in-
dicating good calibration. The respective
ﬁgures were 0.77 (P , 0.0001) and 8.30
(P = 0.4048) from the predictive model
of incident FPG-DM and 0.71 (P ,
0.0001) and 10.36 (P = 0.2407) from
the predictive model of incident FPG/
A1C-DM. The internal validation re-
sults using the bootstrapping method
yielded a bootstrap-corrected AROC
and P value of the Hosmer-Lemeshow
statisticof0.74and0.2585,respectively,
from the predictive model of incident
A1C-DM, indicating high reliability of
discrimination and calibration. The re-
spective ﬁgures were 0.76 and 0.5248
from the predictive model of incident
FPG-DM and 0.70 and 0.3261 from the
Table 1—HbA1c by FPG classiﬁcation based on data from the baseline and second exams
(1989–1995) of the SHS collected from American Indian participants who did not receive
treatments for diabetes, were not on renal dialysis, and did not have a kidney transplant
at the exams
Baseline exam FPG (mg/dL)
(N = 2,849)
Second exam FPG (mg/dL)
(N = 1,670)*
$126 100–125 ,100 $126 100–125 ,100
HbA1c (%)
$6.5
Frequency 314 33 4 71 70 34
Row percentage 89.5 9.4 1.1 40.6 40.0 19.4
Column percentage 54.2 2.5 0.4 40.6 8.2 5.3
6.0–6.4
Frequency 73 92 29 19 66 38
Row percentage 37.6 47.4 15.0 15.5 53.7 30.9
Column percentage 12.6 7.0 3.0 10.9 7.7 5.9
4.75–5.9
Frequency 167 938 603 68 562 371
Row percentage 9.8 54.9 35.3 6.8 56.1 37.1
Column percentage 28.8 71.4 63.1 38.9 65.7 58.0
,4.75
Frequency 25 251 320 17 157 197
Row percentage 4.2 42.1 53.7 4.6 42.3 53.1
Column percentage 4.3 19.1 33.5 9.7 18.4 30.8
*Those participants with FPG $126 mg/dL, HbA1c $6.5%, or on diabetes medications at the baseline exam
were excluded. Row percentage 89.5 = 100 3 314/(314 + 33 + 4). Column percentage 54.2 = 100 3 314/
(314 + 73 + 167 + 25).
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Wang and Associatespredictive model of incident FPG/A1C-
DM.
The predictive model for incident
FPG/A1C-DM using both FPG and
HbA1c at the baseline was signiﬁcantly
better than the predictive model for inci-
dent FPG/A1C-DM obtained by the same
selecting procedures but without consid-
ering the baseline HbA1c (P = 0.0216), or
the one without considering the baseline
FPG (P = 0.0118) (data not shown). Risk
calculatorsbasedontheseproposedmodels
are provided on the SHS Web site for gen-
eral public, clinical physicians, or study
investigators.
CONCLUSIONS—We found that us-
ing HbA1c alone in an initial diabetes
screening among undiagnosed adults
in a population-based sample identiﬁed
fewercasesofprevalentdiabetesthanusing
FPG alone (Table 1). However, for identi-
fying casesofprevalentdiabetesina 4-year
periodic successive diabetes screening or
identifying incident diabetes in 4 years in
undiagnosed participants, each criterion
missed cases of diabetes identiﬁed by the
other(Table1).Wealsoshowed thatusing
both HbA1c and FPG identiﬁed a larger
group of people at risk.
The discordances between diabetes
identiﬁed by HbA1c and glucose criteria
were also found in U.S. 2003–2006 Na-
tional Health and Nutrition Examination
Survey data (18) and in several other
studies in different ethnic groups (19).
In general, HbA1c detected lower preva-
lence of diabetes than glucose criteria in
U.S. and other populations, especially in
undiagnosed participants (4,18,19),
w h i c hi sc o n s i s t e n tw i t ho u rﬁndings in
American Indians.
The discordances between diabetes
identiﬁed by HbA1c and FPG among un-
diagnosed participants may be caused in
partbythefactthatHbA1clevelreﬂectsan
integrated measure of glycemia over a 2-
to 3-month period, whereas FPG reﬂects
theinﬂuenceofhepaticglucoseoutputon
the day of the visit (3,4,20).
We found that in the initial diabetes
screening,amongundiagnosedparticipants
at the baseline exam FPG $126 mg/dL
identiﬁed more cases of diabetes than
HbA1c$6.5%,butinasuccessivediabetes
screening 4 years later, among undiag-
nosed participants the percentages were
equal. The difference between the initial
and successive diabetes screenings may
be because at the baseline exam those
newly diagnosed participants might have
had unrecognized diabetes for many
years, while those newly diagnosed at the
successive exam might have had unrecog-
nized diabetes for at most 4 years. This sup-
ports the contention that HbA1c $6.5%
represents sustained daily hyperglycemia
sufﬁcient to meaningfully inﬂuence glyca-
tion, whereas FPG $126 mg/dL may be a
transientphenomenonthathappensocca-
sionally in many people. With a 4-year
window, there is much less time to de-
velop sustained hyperglycemia, and thus
the two indicators are more comparable.
Since in the usual clinical situation there
Table 2—Comparison of risks of A1C-DM, FPG-DM, or FPG/A1C-DM in 4 years among subgroups of each risk factor after adjusting
for age, sex, and center: the SHS
A1C-DM FPG-DM FPG/A1C-DM
OR 95% CI P OR 95% CI P OR 95% CI P
FPG (mg/dL)
IFG vs. NFG 3.12 2.31–4.22 ,0.0001 2.34 1.81–3.03 ,0.0001
HbA1c (%)
6.0–6.4 vs. ,6.0 5.89 4.23–8.19 ,0.0001 3.43 2.27–5.16 ,0.0001
JNC-7 HTN status
Pre-HTN vs. normal 1.13 0.85–1.51 0.4076 1.50 1.09–2.05 0.0119 1.33 1.00–1.77 0.0491
HTN vs. normal 1.54 1.15–2.07 0.0035 1.63 1.17–2.26 0.0036 1.40 1.04–1.90 0.0270
Obesity status
Overweight vs. normal 1.40 0.94–2.09 0.0962 1.57 0.99–2.51 0.0564 1.50 1.01–2.23 0.0420
Obese vs. normal 2.66 1.83–3.88 ,0.0001 3.73 2.41–5.77 ,0.0001 2.99 2.05–4.34 ,0.0001
Obese vs. overweight 1.90 1.46–2.47 ,0.0001 2.37 1.76–3.19 ,0.0001 1.98 1.53–2.58 ,0.0001
Parental history of diabetes (yes vs. no) 1.63 1.25–2.12 0.0003 1.22 0.92–1.62 0.1735 1.32 1.02–1.72 0.0369
Sibling history of diabetes (yes vs. no) 1.58 1.26–2.00 0.0001 1.64 1.27–2.11 0.0001 1.42 1.12–1.80 0.0040
Albuminuria
Micro- vs. normal 1.97 1.39–2.80 0.0001 2.69 1.88–3.85 ,0.0001 2.38 1.66–3.40 ,0.0001
Macro- vs. normal 1.93 0.98–3.80 0.0557 2.43 1.26–4.70 0.0083 1.27 0.56–2.84 0.5682
Metabolic syndrome traits (yes vs. no)
Elevated blood pressure 1.56 1.23–1.99 0.0003 1.68 1.29–2.18 0.0001 1.56 1.22–1.99 0.0003
HyperTG 1.51 1.19–1.93 0.0009 1.61 1.23–2.10 0.0005 1.54 1.20–1.98 0.0008
LowHDL-C 1.51 1.19–1.90 0.0006 1.61 1.24–2.08 0.0003 1.55 1.22–1.96 0.0003
HighWAIST 2.61 1.92–3.56 ,0.0001 3.88 2.69–5.59 ,0.0001 2.43 1.79–3.30 ,0.0001
The risk-factor data from the baseline exam and the incident diabetes status data from the second exam collected from participants without A1C-DM, FPG-DM, or
FPG/A1C-DM at the baseline exam were used to obtain the results for cumulative incident A1C-DM, FPG-DM, and FPG/A1C-DM, respectively. Albuminuria =
normal,UACR,30mg/g;micro-,30#UACR,300mg/g;and macro-,300mg/g#UACR.FPG-DM=diabetes,FPG$126mg/dLorondiabetesmedications;IFG,
100 # FPG , 126 mg/dL; and NFG, FPG ,100 mg/dL. FPG/A1C-DM = diabetes, FPG $126 mg/dL or HbA1c $6.5%, or on diabetes medications; nondiabetic
otherwise. Obesity = normal, BMI ,25 kg/m
2; overweight, 25 # BMI , 30 kg/m
2; obese, BMI $30 kg/m
2. A1C-DM = diabetes, HbA1c $6.5% or on diabetes
medications;nondiabeticotherwise.JNC-7HTNstatus=normal,SBP,120mmHgandDBP,80mmHg;Pre-HTN,120#SBP,140mmHgandDBP,90mmHg,
or SBP ,140 and 80 # DBP , 90 mmHg; HTN, SBP $140 or DBP $90 or on HTN medications. Metabolic syndrome traits = elevated blood pressure, SBP $130
mmHg,DBP$85mmHg,oronHTNmedications.highWAIST=WAIST.102cminmenor.88cminwomen.hyperTG=TGs$150mg/dL.lowHDL-C=HDL-C
,40 mg/dL in men or ,50 mg/dL in women. Data in bold are signiﬁcant.
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FPG/HbA1c in identifying and predicting diabeteshas not been a screening in the near past,
the discrepancy between HbA1c and FPG
would likely prevail. The similar differ-
ence between the initial and successive di-
abetes screenings by using FPG and 2-h
post plasma glucose was also reported in
American Indians (21).
Ourdatashowthatalargernumberof
peopleat risk can beidentiﬁed usingboth
HbA1c andFPG.Onecost-effectivediabe-
tes screening procedure could be to 1)
measure HbA1c for all participants and
2) further measure FPG only for those
participants with 4.75% # HbA1c ,
6.5%, since our data show this would re-
sult in the identiﬁcation of the most of
remainder of those who would have dia-
betes by FPG criterion (Table 1). Others
have also reported that using a method
b a s e do nF P Ga n dH b A 1c in diabetes
screening was more efﬁcient (21).
The ﬁnal set of variables in our model
for predicting incident diabetes was se-
lected among those reported variables in
the literature (11–13) plus AEHPW, years
of education, current alcohol intake,
HbA1c, UACR, and additional interactions
and nonlinear terms of these predictors.
Each risk factor in the proposed models
was associated signiﬁcantly and indepen-
dentlyto incident diabetes.Further studies
are needed to see whether the risk-factor
sets, independent contributions, and non-
linearity still hold if data from other popu-
lations are used. Prediction models for
diagnosis using either criterion were simi-
lar, with majorbaseline variables including
glycemia by either measure, obesity,
WAIST, and UACR. Obesity and WAIST
were important determinants; the latter, a
reﬂection of abdominal fat, is closely asso-
ciated with hyperinsulinemia and insulin
resistance (22)and thus reﬂectsthe impor-
tance of insulin resistance as a determinant
of type 2 diabetes. Glycemia, measured ei-
ther by HbA1c or FPG, depending on the
model,wasalsoanimportantdeterminant;




and inﬂammation, is also an important de-
terminantinallmodels,whichisconsistent
with our previous demonstrations that
albuminuria is an important risk factor
for diabetes, HTN, and CVD in American
Indians (6,23,24). The associations of
HbA1c,FPG,andLog(UACR)withincident
diabetes were nonlinear, as evident by the
quadratic forms of HbA1c, FPG, and Log
(UACR)enteredinsteadoftheprimaryvar-
iables in the predictive models. For HbA1c
this meant also that it changed directions
from negative to positive association to
incident diabetes at about HbA1c =4 . 7 % .
The reason why HbA1c changed the direc-
tion of the association at about 4.7% was
not clear and needs further study. Meta-
bolic syndrome traits of elevated blood
pressure and hyperTG also signiﬁcantly
predict incident diabetes in our models,
similar to previous reports in the literature
(12,25). This is likely because they also re-
ﬂect insulin resistance.
The models for predicting incident
A1C-DM, FPG-DM, or FPG/A1C-DM
were all internally validated. The predic-
tive model for incident FPG/A1C-DM
using both FPG and HbA1c at the baseline
was signiﬁcantly better than the model
without considering the baseline FPG or
HbA1c.
This study has many strengths, in-
cluding population-based sampling and
systematic measures at two exams; fur-
ther, this is a unique population that may
become a reference for other populations
with high rates of diabetes and diabetic
CVD.Duetothehighprevalence(;46%)
of diabetes in American Indians, we are
only able to use data collected from about
half of 4,549 participants in the SHS co-
hort to derive predictive equations. Al-
though our proposed models were
internallyvalidated,theyshouldbetested
and validated in other populations.
Table 3—Predictive models for 4-year cumulated incidence of diabetes: the SHS
Unit
A1C-DM* FPG-DM* FPG/A1C-DM*
Coeff. P OR† 95% CI Coeff. P OR† 95% CI Coeff. P OR† 95% CI
Intercept 11.088 0.0076 27.223 ,0.0001 11.354 0.0049
Age (years) 5 20.033 0.0001 0.85 0.78–0.92 20.033 0.0003 0.85 0.77–0.93 20.029 0.0004 0.86 0.80–0.94
WAIST (cm) 10.0 0.011 0.0130 1.12 1.02–1.23 0.017 0.0003 1.18 1.08–1.30
highWAIST 1.0 0.770 ,0.0001 2.16 1.52–3.14
Elevated blood
pressure 1.0 0.326 0.0263 1.39 1.04–1.85 0.286 0.0293 1.33 1.03–1.72
FPG (mg/dL) 10.0 0.028 ,0.0001 1.33 1.23–1.44
FPG 3 FPG 0.000 ,0.0001 0.000 ,0.0001
HbA1c (%) 0.5 27.408 ,0.0001 0.620 ,0.0001 1.36 1.23–1.53 26.480 ,0.0001
HbA1c 3 HbA1c 0.794 ,0.0001 0.686 ,0.0001
Log(UACR) 3
Log(UACR) 0.021 0.0015 0.032 ,0.0001 0.019 0.0047
Log(TG) 0.332 0.0090
hyperTG 1.0 0.372 0.0060 1.45 1.11–1.89
Sibling history of
diabetes 1.0 0.342 0.0158 1.41 1.07–1.86
AROC 0.75 ,0.0001‡ 0.77 ,0.0001‡ 0.71 ,0.0001‡
Hosmer–Lemeshow
statistic 11.23 0.1889§ 8.30 0.4048§ 10.36 0.2407§
The risk-factor data from the baseline exam and the incident diabetes status data from the second exam collected from participants without A1C-DM, FPG-DM, or
FPG/A1C-DMatthebaselineexamwereusedtoobtainthepredictivemodelforcumulativeincidentA1C-DM,FPG-DM,andFPG/A1C-DM,respectively.Variablesin
themodelswereselectedaccordingtotheproceduresexplainedinthestatisticalanalysessection.Coeff.,estimatedregressioncoefﬁcient.*Seerespectivedeﬁnitionsin
Table 2. †Related to the unit increment. ‡P value from testing whether AROC = 0.5. §P value from testing whether Hosmer–Lemeshow statistic = 0.
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Wang and AssociatesIn conclusion, FPG and HbA1c crite-
ria do not identify identical groups of
individualsfromapopulation-basedsam-
pleashavingdiabetes. UsingHbA1c alone
to conduct an initial diabetes screening in
undiagnosed participants detects fewer
cases of prevalent diabetes than FPG
alone. However, for identifying cases of
prevalent diabetes in a 4-year periodic
successive diabetes screening or identify-
ing cases of incident diabetes in 4 years in
undiagnosed participants, using either
FPG or HbA1c alone was not effective.
Baseline FPG or HbA1c levels, WAIST,
and UACR were common signiﬁcant
and independent risk factors for incident
diabetesdeﬁnedbyeitherFPG-orHbA1c-
based criteria. Using both the baseline
FPG and HbA1c to predict incident FPG/
A1C-DM identiﬁed more people at risk.
The proposed models can be applied to
assess risk of incident A1C-DM, FPG-DM,
or FPG/A1C-DM in American Indians and
have potential applicability to other popu-
lations.
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